NASDAQ:PDLI - PDL BioPharma Stock Price, Forecast & News

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

PDL BioPharma declared that its Board of Directors has approved a stock repurchase program on Monday, September 24th 2018, which permits the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 27.3% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

PDL BioPharma Inc (NASDAQ:PDLI) released its earnings results on Wednesday, August, 8th. The biotechnology company reported $0.10 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.04. The biotechnology company had revenue of $46.58 million for the quarter. View PDL BioPharma's Earnings History.

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for PDL BioPharma.

1 Wall Street analysts have issued 1 year target prices for PDL BioPharma's stock. Their forecasts range from $3.00 to $3.00. On average, they expect PDL BioPharma's stock price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 16.9%. View Analyst Price Targets for PDL BioPharma.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma.

News articles about PDLI stock have been trending negative on Thursday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PDL BioPharma earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for PDL BioPharma.

PDL BioPharma saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 10,150,000 shares, a decline of 27.3% from the December 31st total of 13,960,000 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is currently 7.7 days. Approximately 9.1% of the company's stock are sold short. View PDL BioPharma's Current Options Chain.

Some companies that are related to PDL BioPharma include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), Opko Health (OPK), Canopy Growth (CGC), Novavax (NVAX), Advanced Micro Devices (AMD), Teva Pharmaceutical Industries (TEVA), Bank of America (BAC), General Electric (GE), Cara Therapeutics (CARA) and Gilead Sciences (GILD).

PDL BioPharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (7.16%), Engine Capital Management LP (5.43%), Brandes Investment Partners LP (5.09%), Connor Clark & Lunn Investment Management Ltd. (3.51%), Charles Schwab Investment Management Inc. (3.04%) and State Street Corp (2.90%). View Institutional Ownership Trends for PDL BioPharma.

PDLI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, UBS Group AG, Goldman Sachs Group Inc., Connor Clark & Lunn Investment Management Ltd., Chicago Equity Partners LLC, State Board of Administration of Florida Retirement System, SG Americas Securities LLC and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for PDL BioPharma.

PDLI stock was bought by a variety of institutional investors in the last quarter, including Engine Capital Management LP, Newtyn Management LLC, Ancora Advisors LLC, Context Capital Management LLC, AQR Capital Management LLC, Brandes Investment Partners LP, Thrivent Financial for Lutherans and Caxton Associates LP. View Insider Buying and Selling for PDL BioPharma.

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PDLI stock can currently be purchased for approximately $3.61.

PDL BioPharma has a market capitalization of $412.19 million and generates $198.11 million in revenue each year. The biotechnology company earns $-68,860,000.00 in net income (profit) each year or $0.37 on an earnings per share basis. PDL BioPharma employs 105 workers across the globe.View Additional Information About PDL BioPharma.

The official website for PDL BioPharma is http://www.pdl.com/.

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]